Hims jumps after RFK Jr. announces FDA may loosen regulations for 12 peptides
Hims & Hers rose more than 13% on Wednesday and continued to rise in premarket trading on Thursday after Health Secretary Robert F. Kennedy Jr. said that the Food and Drug Administration may ease restrictions on 12 peptides.
The move would allow compounding pharmacies to dispense the list of peptides, which have grown in popularity but are currently available only through suppliers who sell them for research purposes.
Hims and other consumer health companies have positioned themselves to begin selling peptides after getting the FDA nod.
Today, we took long-overdue action to restore science, accountability, and the rule of law.
— Secretary Kennedy (@SecKennedy) April 15, 2026
In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts…
CEO Andrew Dudum told investors in February that the company is actively exploring expanding into “peptide therapies.” The company has a network of its own compounding pharmacies, as well as a peptide facility in California that it acquired last year.
“Our medical team believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives, and we are actively exploring how to expand access in a way that will be aligned with FDA guidance and reflects our commitment to consumer safety, transparency, and clinical excellence,” Hims Chief Medical Officer Dr. Pat Carrol said in a statement Wednesday.
Hims rallied on the news, though the stock was still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.
Hims and other consumer health companies have positioned themselves to begin selling peptides after getting the FDA nod.
Today, we took long-overdue action to restore science, accountability, and the rule of law.
— Secretary Kennedy (@SecKennedy) April 15, 2026
In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts…
CEO Andrew Dudum told investors in February that the company is actively exploring expanding into “peptide therapies.” The company has a network of its own compounding pharmacies, as well as a peptide facility in California that it acquired last year.
“Our medical team believes certain peptide therapies hold meaningful potential in helping Americans live healthier lives, and we are actively exploring how to expand access in a way that will be aligned with FDA guidance and reflects our commitment to consumer safety, transparency, and clinical excellence,” Hims Chief Medical Officer Dr. Pat Carrol said in a statement Wednesday.
Hims rallied on the news, though the stock was still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.
